INTRODUCTION {#s1}
============

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer, predominantly includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma, accounts for about 80% of lung cancers. Adenosquamous lung carcinoma is a relatively rare subtype of non-small cell lung cancer comprising of 0.3% to 5% of all non-small cell lung cancers \[[@R1], [@R2]\].

According to criteria of World Health Organization, adenosquamous lung carcinoma is a carcinoma displaying components of both squamous cell carcinoma and adenocarcinoma, with each component comprising at least 10% of the tumor \[[@R3]\]. Adenosquamous lung carcinoma is regarded as more aggressive and carries a worse prognosis compared to adenocarcinoma and squamous cell carcinoma \[[@R1], [@R4]\]. However, its biological behaviors based on clinicopathological factors are not well understood. Most adenosquamous lung carcinoma patients eventually develop local recurrence and/or distant metastasis even after complete tumor resection, and the overall survival rates remain low. Standard platinum-based doublet chemotherapy of advanced non-small cell lung cancer has limited efficacy, thus new therapies are needed.

Recent advancements in EGFR mutation targeted therapy led to a major paradigm shift in the treatment of non-small cell lung cancer. EGFR-sensitizing mutations are strongly associated with robust responses to EGFR tyrosine kinase inhibitors (EGFR-TKI) and improved progression-free survival (PFS). However, EGFR mutations are most common in Asian patients, nonsmokers, females and those with adenocarcinoma histology \[[@R5]\]. In squamous cell carcinoma, the EGFR mutation rate is reported to be approximately 5% \[[@R6]\]. Although several small studies have indicated that the frequency of EGFR mutation in adenosquamous lung carcinoma ranges from 15% to 44% in the East Asian population, the exact prevalence of EGFR mutation in adenosquamous lung carcinoma is still not clear.

In recent years, serum tumor markers, including neuron-specific enolase (NSE) \[[@R7]-[@R9]\], carcinoembryonic antigen (CEA) \[[@R10], [@R11]\], cytokeratin-19 fragments (Cyfra21-1) \[[@R12]\] and squamous cell carcinoma antigen (SCCA) \[[@R13]\] have been extensively investigated, and considered potentially predictive and prognostic in non-small cell lung cancer. However, little is known about the predictive and prognostic value of the tumor markers in patients with adenosquamous lung carcinoma. Here, we investigated the clinicopathological characteristics of adenosquamous lung carcinoma patients who underwent surgery and explored the predictive and prognostic value of serum tumor markers NSE, CEA, Cyfra21-1 and SCCA.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

The clinical characteristics of the 106 adenosquamous lung carcinoma patients are shown in Table [1](#T1){ref-type="table"}. Sixty-three patients (59.4%) were men and 42 (39.6%) were never-smokers, with an age range of 35 to 83 years (median, 60 years). Among the patient histology, 49 (46.3%) were adenocarcinoma predominant, 26 (24.5%) squamous cell carcinoma predominant, and 31 (29.2%) with equal adenocarcinoma and squamous cell carcinoma. The distribution of clinical stages was as follows: 41 stage I, 19 stage II, and 46 stage IIIA. Eight patients (7.5%) received pneumonectomy, 89 (84.0%) received lobectomy, and 9 (8.5%) underwent wedge resection. EGFR mutations were detected in 27.4% (29/106) of 106 patients. Among the 29 patients with mutations, 13 harbored exon 19 deletions (del19), 13 had point mutations in exon 21 (12 were L858R, and one was L861Q), two had G719X in exon 18, and one possessed dual mutations of G719X in exon 18 and S768I in exon 20. No T790M mutations were detected in these patients.

Of the 106 adenosquamous lung carcinoma patients, 63 (59.5%) were treated with platinum-based adjuvant chemotherapy, 10 (9.4%) underwent platinum-based adjuvant chemoradiotherapy, and 68 (64.2%) had recurrent disease during the study follow-up period. The median DFS was 15.0 months (95% confidence interval \[CI\]: 9.5-20.4). In addition, 43 (40.6%) recurrent patients received systemic chemotherapy, 28 (26.4%) patients also received radiotherapy as local therapy, and only 5 (4.7%) received EGFR-TKIs. At the end of the last follow up, 69 (65.1%) patients had died. Median overall survival was 26.0 months. The survival rates of 1, 2 and 5-year were 76.4%, 52.9%, and 25.3%, respectively. Among the 68 patients with recurrent disease, the initially recurrent sites were the loco-regional or lung (33.8%, 23/68), bone (10.3%, 7/68), brain (16.2%, 11/68) and liver (7.3%, 5/68), 22 (32.4%) patients had multiple recurrent sites.

###### Patient characteristics

  Variable                                          No. of Patients   \%
  ------------------------------------------------- ----------------- ------
  Age (years)                                                         
  Median (range)                                    60 (35-83)        
  \< 60                                             50                47.2
  ≥ 60                                              56                52.8
  Gender                                                              
  Male                                              63                59.4
  Female                                            43                40.6
  Smoking history                                                     
  Never                                             42                39.6
  Ever                                              64                60.4
  Component                                                           
  Adenocarcinoma predominant                        49                46.3
  Squamous cell carcinoma predominant               26                24.5
  Equal proportion                                  31                29.2
  Clinical stage                                                      
  I                                                 41                38.7
  II                                                19                17.9
  IIIA                                              46                43.4
  Tumor size                                                          
  ≤ 3 cm                                            36                44.0
  \> 3 cm                                           70                56.0
  Regional lymph node metastasis                                      
  No                                                47                44.3
  Yes                                               59                55.7
  Operative approaches                                                
  Pneumonectomy                                     8                 7.5
  Lobectomy                                         89                84.0
  Wedge resection                                   9                 8.5
  Adjuvant treatment                                                  
  Chemotherapy                                      63                59.5
  Chemoradiotherapy                                 10                9.4
  Others/none                                       33                31.1
  EGFR mutation                                                       
  Wild-type                                         77                72.6
  Exon 19 deletion                                  13                12.3
  L858R substitution                                12                11.3
  Others                                            4                 3.8
  NSE                                                                 
  ≤ 15.2 ng/ml                                      68                64.2
  \> 15.2 ng/ml                                     38                35.8
  CEA                                                                 
  ≤ 5.0 ng/ml                                       56                52.8
  \> 5.0 ng/ml                                      50                47.2
  Cyfra21-1                                                           
  ≤ 3.3 ng/ml                                       48                45.3
  \> 3.3 ng/ml                                      58                54.7
  SCCA                                                                
  ≤ 1.5 ng/ml                                       90                84.9
  \> 1.5 ng/ml                                      16                15.1
  Tumor marker index (TMI)                                            
  ≤ 0.54                                            17                16.0
  \> 0.54                                           89                84.0
  Recurrent sites (n = 68)                                            
  Loco-regional or lung                             23                33.8
  Bone                                              7                 10.3
  Brain                                             11                16.2
  Liver                                             5                 7.3
  Multiple                                          22                32.4
  Post-recurrence treatment Systemic chemotherapy                     
  No                                                63                50.4
  Yes                                               43                40.6
  Radiotherapy                                                        
  No                                                78                73.6
  Yes                                               28                26.4
  EGFR-TKI                                                            
  No                                                101               95.3
  Yes                                               5                 4.7
  Total                                             106               100

Association of serum tumor marker levels with clinicopathological characteristics {#s2_2}
---------------------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"}, preoperative NSE, CEA, Cyfra21-1 and SCCA levels were elevated in 35.8%, 47.2%, 54.7% and 15.1% of adenosquamous lung carcinoma patients, respectively. Elevated preoperative NSE levels were closely associated with advanced clinical stage (*P* = 0.006), smoking history (*P* = 0.036) and regional lymph node metastasis (*P* = 0.005). In addition, median NSE levels in patients with larger tumor size were higher than those with smaller tumor size (14.7 *versus* 13.7 ng/ml, *P* = 0.045). And increased SCCA levels were found to be correlated with tumor size (*P* = 0.011). Neither CEA nor Cyfra21-1 levels were correlated with any clinical parameter in adenosquamous lung carcinoma patients. Median levels and positive rates for NSE, CEA, Cyfra21-1 or SCCA were similar regardless of EGFR mutation status in adenosquamous lung carcinoma patients. Similarly, no differences were found in positive rates and median levels of these tumor markers between del19 and L858R subtypes.

Moreover, as shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}, EGFR mutations were found more frequently in women (48.8% *versus* 12.7%, χ^2^ = 16.795, *P* \< 0.001), never-smokers (42.9% *versus* 17.2%, χ^2^ = 8.408, *P* = 0.004) and younger patients (36.0% *versus* 19.6%, χ^2^ = 3.556, *P* = 0.059).

###### The association between serum tumor markers and the clinicopathological characteristics

  Variable                                       NSE median (IQR)   CEA median (IQR)   Cyfra21-1 median (IQR)   SCCA median (IQR)   NSE \> 15.2 ng/ml (%)   CEA \> 5.0 ng/ml (%)   Cyfra21-1 \> 3.3 ng/ml (%)   SCCA \> 1.5 ng/ml (%)
  ---------------------------------------------- ------------------ ------------------ ------------------------ ------------------- ----------------------- ---------------------- ---------------------------- -----------------------
  Component                                                                                                                                                                                                     
  Adenocarcinoma predominant (n = 49)            14.2 (11.6-18.3)   5.5 (3.0-16.1)     3.8 (2.4-5.1)            0.8 (0.4-1.3)       18 (36.7)               26 (53.0)              27 (55.1)                    7 (14.3)
  Squamous cell carcinoma predominant (n = 26)   14.7 (12.8-20.6)   5.7 (3.2-13.9)     3.5 (2.5-5.3)            0.8 (0.5-1.0)       11 (42.3)               15 (57.7)              17 (65.4)                    3 (11.5)
  Equal proportion (n = 31)                      13.8 (10.5-16.2)   3.3 (2.2-7.0)      3.0 (2.1-5.2)            0.7 (0.3-1.3)       9 (29.0)                9 (29.0)               14 (45.2)                    6 (19.4)
  *P*-value                                      0.079              0.169              0.568                    0.987               0.573                   0.052                  0.310                        0.735
  Clinical stage                                                                                                                                                                                                
  I (n = 41)                                     13.5 (11.4-13.5)   3.6 (2.2-11.6)     3.2 (2.1-4.6)            0.8 (0.3-1.2)       7 (17.1)                16 (39.0)              20 (48.8)                    3 (7.3)
  II ( n = 19)                                   15.1 (11.6-19.0)   5.3 (3.0-8.8)      3.5 (2.5-5.2)            1.0 (0.5-1.8)       9 (47.4)                10 (52.6)              11 (57.9)                    5 (26.3)
  IIIA ( n = 46)                                 14.9 (12.1-18.6)   5.2 (3.0-21.9)     4.0 (2.4-5.3)            0.7 (0.4-1.2)       22 (47.8)               24 (52.2)              27 (58.7)                    8 (17.4)
  *P*-value                                      0.016              0.484              0.422                    0.642               0.006                   0.517                  0.620                        0.205
  Tumor size                                                                                                                                                                                                    
  ≤ 3 cm (n = 36)                                13.7 (11.6-15.6)   3.3 (2.0-9.6)      3.3 (1.9-4.2)            0.6 (0.4-1.0)       10 (27.8)               14 (38.9)              18 (50.0)                    1 (2.7)
  \> 3 cm (n = 70)                               14.7 (12.1-18.5)   5.2 (3.0-15.6)     3.9 (2.5-5.4)            0.9 (0.4-1.3)       28 (40.0)               36 (51.4)              40 (57.1)                    15 (21.4)
  *P*-value                                      0.045              0.448              0.241                    0.207               0.214                   0.221                  0.484                        0.011
  Regional lymph node metastasis                                                                                                                                                                                
  No (n = 59)                                    13.7 (11.6-15.0)   3.2 (2.2-12.3)     3.2 (2.0-5.2)            0.9 (0.3-1.4)       28 (47.5)               32 (54.2)              35 (59.3)                    10 (16.9)
  Yes (n = 47)                                   15.1 (12.0-19.0)   5.3 (3.2-16.3)     3.8 (2.5-5.2)            0.7 (0.4-1.2)       10 (21.3)               18 (38.3)              23 (48.9)                    6 (12.8)
  *P*-value                                      0.092              0.197              0.370                    0.534               0.005                   0.102                  0.293                        0.550
  EGFR mutation                                                                                                                                                                                                 
  Wild-type (n = 77)                             14.3 (12.4-18.3)   4.1 (2.7-12.4)     3.7 (2.5-5.3)            0.9 (0.4-1.3)       29 (37.7)               33 (42.9)              45 (58.4)                    14 (19.2)
  Exon 19 deletion (n = 13)                      12.3 (10.6-16.6)   5.2 (3.2-23.4)     2.5 (1.8-3.9)            0.6 (0.5-0.8)       4 (30.8)                7 (53.8)               6 (46.2)                     0 (0.0)
  L858R substitution (n = 12)                    14.4 (12.2-25.0)   6.9 (2.2-16.3)     2.8 (1.6-5.4)            0.6 (0.4-1.0)       4 (33.3)                7 (58.3)               5 (41.7)                     1 (9.1)
  Others (n = 4)                                 14.6 (10.5-20.0)   5.9 (3.6-8.3)      3.6 (2.8-4.2)            1.8 (0.4-2.3)       1 (25.0)                3 (75.0)               2 (50.0)                     1 (25.0)
  *P*-value                                      0.679              0.314              0.801                    0.062               0.977                   0.477                  0.621                        0.277
  Total (n = 106)                                14.3 (11.9-18.3)   4.6 (2.7-13.0)     3.5 (2.4-5.2)            0.8 (0.4-1.25)      38 (35.8)               50 (47.2)              58 (54.7)                    16 (15.1)

Association of serum tumor markers, TMI and EGFR mutation status with DFS and OS {#s2_3}
--------------------------------------------------------------------------------

Among the 106 adenosquamous lung carcinoma patients, 38 had elevated NSE levels, 50 elevated CEA, 58 elevated Cyfra21-1 and 16 elevated SCCA. DFS and OS were significantly shorter in patients with elevated NSE (9.6 *versus* 20.5 months, log-rank χ^2^ = 9.638, *P* = 0.002 for DFS, Figure [1A](#F1){ref-type="fig"}; 16.0 *versus* 36.0 months, log-rank χ^2^ = 15.330, *P* \< 0.001 for OS, Figure [1B](#F1){ref-type="fig"}). Patients with elevated Cyfra21-1 exhibited similar DFS (14.8 *versus* 15.0 months, log-rank χ^2^ = 0.017, *P* = 0.897, Figure [1C](#F1){ref-type="fig"}) but shorter OS (22.0 *versus* 37.0 months, log-rank χ^2^ =3.533, *P* = 0.060, Figure [1D](#F1){ref-type="fig"}). Neither CEA nor SCCA was correlated with any effect on DFS or OS (CEA: *P* = 0.565 for DFS, Figure [1E](#F1){ref-type="fig"}; *P* = 0.604 for OS, Figure [1F](#F1){ref-type="fig"}; SCCA: *P* = 0.796 for DFS, Figure [1G](#F1){ref-type="fig"}; *P* = 0.940 for OS, Figure [1H](#F1){ref-type="fig"}).

![Kaplan-Meier survival curves of DFS and OS based on different levels of serum tumor markers\
**A.** DFS and **B.** OS based on different levels of NSE; **C.** DFS and **D.** OS based on different levels of Cyfra21-1; **E.** DFS and **F.** OS based on different levels of CEA; **G.** DFS and **H.** OS based on different levels of SCCA;](oncotarget-07-64798-g001){#F1}

The relationship between the TMI and survival in adenosquamous lung carcinoma patients is shown in Figure [2](#F2){ref-type="fig"}. There were 17 patients with TMI ≤ 0.54 and 89 patients with TMI \> 0.54. The OS of patients with a TMI ≤ 0.54 was longer than patients with a TMI \> 0.54 but no difference in DFS was found between the two groups (47.0 *versus* 14.0 months, log-rank χ^2^ = 3.600, *P* = 0.058 for DFS, Figure [2A](#F2){ref-type="fig"}; Not Reached \[NR\] *versus* 24.0 months, log-rank χ^2^ = 7.534, *P* = 0.006 for OS, Figure [2B](#F2){ref-type="fig"}).

Moreover, in those patients with stage II and IIIA diseases, elevated NSE levels were associated with shorter DFS and OS (9.6 *versus* 15.3 months, log-rank χ^2^ = 5.036, *P* = 0.025 for DFS, Figure [2C](#F2){ref-type="fig"}; 15.5 *versus* 34.0 months, log-rank χ^2^ = 8.479, *P* = 0.004 for OS, Figure [2D](#F2){ref-type="fig"}), while this relationship between increased NSE and DFS or OS was not found in stage I patients.

As shown in Table [3](#T3){ref-type="table"}, similar DFS and OS were observed in patients regardless of EGFR mutation status (*P* = 0.893 for DFS; *P* = 0.642 for OS). Of the 29 adenosquamous lung carcinoma patients with EGFR mutations, no difference was found in DFS and OS between del19 and L858R subgroups (*P* = 0.595 for DFS; *P* = 0.778 for OS).

###### Univariate analysis of DFS and OS

                                        DFS    OS                                                          
  ------------------------------------- ------ --------------------- ------- ------ ---------------------- ----------
  Total (n = 106) Age (years)                                                                              
  \< 60                                 12.1   Reference             0.492   34.1   Reference              0.159
  ≥ 60                                  16.5   0.846 (0.526-1.362)           22.0   1.411 (0.874-2.280)    
  Gender                                                                                                   
  Male                                  14.0   Reference             0.237   24.5   Reference              0.619
  Female                                15.5   1.350 (0.821-2.221)           29.0   1.132 (0.695-1.844)    
  Smoking history                                                                                          
  Never                                 15.0   Reference             0.461   27.8   Reference              0.986
  Ever                                  15.0   1.206 (0.733-1.986)           38.7   0.996 (0.610-1.624)    
  Component                                                                                                
  Adenocarcinoma predominant            12.1   Reference             0.645   24.5   Reference              0.780
  Squamous cell carcinoma predominant   19.0   0.777 (0.429-1.408)           34.0   0.910 (0.507-1.635)    
  Equal proportion                      15.3   0.819 (0.462-1.453)           33.8   0.816 (0.463-1.440)    
  Clinical stage                                                                                           
  I                                     32.0   Reference             0.009   42.0   Reference              0.046
  II                                    15.5   1.447 (0.706-2.966)           19.5   1.652 (0.815-3.550)    
  IIIA                                  9.6    2.335 (1.345-4.052)           24.0   1.963 (1.148-3.357)    
  Tumor size                                                                                               
  ≤ 3 cm                                47.0   Reference             0.001   43.0   Reference              0.002
  \> 3 cm                               9.9    2.733 (1.532-4.877)           20.5   2.434 (1.403-4.225)    
  Regional lymph node metastasis                                                                           
  No                                    32.0   Reference             0.024   37.0   Reference              0.030
  Yes                                   12.1   1.775 (1.080-2.918)           22.0   1.720 (1.055-2.804)    
  Operative approaches                                                                                     
  Pneumonectomy                         12.5   Reference             0.203   16.0   Reference              0.167
  Lobectomy                             15.5   0.511 (0.242-1.078)           26.0   0.552 (0.247-1.103)    
  Wedge resection                       10.0   0.631 (0.218-1.802)           29.0   0.778 (0.291-2.081)    
  Adjuvant treatment                                                                                       
  Chemotherapy                          14.8   Reference             0.538   25.2   Reference              0.720
  Chemoradiotherapy                     9.6    1.372 (0.667-2.823)           25.5   0.782 (0.333-1.836)    
  Others/none                           16.5   0.867 (0.493-1.524)           36.0   0.830 (0.484-1.423)    
  EGFR mutation                                                                                            
  Wild-type                             15.3   Reference             0.893   33.8   Reference              0.642
  Mutant                                14.0   0.963 (0.560-1.656)           25.5   0.877 (0.504-1.527)    
  NSE                                                                                                      
  ≤ 15.2 ng/ml                          20.5   Reference             0.002   36.0   Reference              \< 0.001
  \> 15.2 ng/ml                         9.6    2.103 (1.300-3.401)           16.0   2.504 (1.555-4.031)    
  CEA                                                                                                      
  ≤ 5.0 ng/ml                           15.3   Reference             0.566   25.9   Reference              0.605
  \> 5.0 ng/ml                          14.8   1.150 (0.713-1.856)           25.4   1.133 (0.706-1.819)    
  Cyfra21-1                                                                                                
  ≤ 3.3 ng/ml                           15.0   Reference             0.897   37.0   Reference              0.063
  \> 3.3 ng/ml                          14.8   1.032 (0.639-1.666)           22.0   1.593 (0.975-2.601)    
  SCCA                                                                                                     
  ≤ 1.5 ng/ml                           15.0   Reference             0.723   27.0   Reference              0.986
  \> 1.5 ng/ml                          9.6    0.881 (0.436-1.780)           14.5   0.994 (0.491-2.011)    
  Tumor marker index (TMI)                                                                                 
  ≤ 0.54                                47.0   Reference             0.063   NR     Reference              0.009
  \> 0.54                               14.0   2.020 (0.961-4.246)           24.0   3.071 (1.320-7.142)    
  Clinical stage I (n = 41) NSE                                                                            
  ≤ 15.2 ng/ml (n = 33)                 32.0   Reference             0.147   42.0   Reference              0.132
  \> 15.2 ng/ml (n = 8)                 9.0    2.017 (0.781-5.209)           15.2   2.027 (0.809-5.081)    
  TMI                                                                                                      
  ≤ 0.54 (n = 11)                       NR     Reference             0.213   NR     Reference              0.113
  \> 0.54 (n = 30)                      15.0   1.998 (0.671-5.949)           36.0   2.399 (0.812-7.090)    
  Clinical stage II-IIIA (n = 65) NSE                                                                      
  ≤ 15.2 ng/ml (n = 35)                 15.3   Reference             0.028   34.0   Reference              0.005
  \> 15.2 ng/ml (n = 30)                9.6    1.926 (1.075-3.453)           15.5   2.345 (1.296-4.243)    
  TMI                                                                                                      
  ≤ 0.54 (n = 6)                        7.6    Reference             0.360   NR     Reference              0.092
  \> 0.54 (n = 59)                      12.5   1.632 (0.571-4.663)           20.7   3.409 (0.817-14.217)   

![Kaplan-Meier survival curves of DFS and OS based on TMI as well as NSE levels\
**A.** DFS and **B.** OS based on different levels of TMI. **C.** DFS and **D.** OS based on different NSE levels in stage II-IIIA patients (*n* = 65).](oncotarget-07-64798-g002){#F2}

Univariate and multivariate analysis of prognostic factors {#s2_4}
----------------------------------------------------------

By univariate analysis, advanced clinical stage (*P* = 0.009 for DFS; *P* = 0.046 for OS), larger tumor size (*P* = 0.001 for DFS; *P* = 0.002 for OS), regional lymph node metastasis (*P* = 0.024 for DFS; *P* = 0.030 for OS), higher NSE level (*P* = 0.002 for DFS; *P* \< 0.001 for OS), and higher TMI (*P* = 0.009 for OS) were significantly correlated with a worse prognosis (Table [3](#T3){ref-type="table"}).

By multivariate analysis, elevated NSE (hazard ratio \[HR\] = 1.862; 95% CI: 1.131-3.066; *P* = 0.014) was confirmed as independent predictors for DFS, while increased NSE (HR = 2.199; 95% CI: 1.355-3.568; *P* = 0.001) and TMI (HR = 2.479; 95% CI: 1.050-5.855, *P* = 0.038) were independent prognostic factors for OS (Table [4](#T4){ref-type="table"}).

###### Multivariate analysis of DFS and OS

                                                          DFS                           OS            
  ----------------------------------------------- ------- ------------- ------- ------- ------------- -------
  Clinical stage (I vs. II-IIIA)                  1.589   0.922-2.738   0.096                         
  NSE (\> 15.2 ng/ml vs. ≤ 15.2 ng/ml )           1.862   1.131-3.066   0.014   2.199   1.355-3.568   0.001
  Tumor marker index (TMI) (\> 0.54 vs. ≤ 0.54)                                 2.479   1.050-5.855   0.038

DISCUSSION {#s3}
==========

Preoperative serum tumor markers secreted by tumor cells might reflect intratumor heterogeneity, and have been investigated as tools for predicting disease progression, either alone, or in combination with clinical variables \[[@R14]\]. However, the predictive and prognostic significance of the tumor markers for adenosquamous lung carcinoma remains largely unknown. EGFR mutations are most common in adenocarcinoma, while their frequency in the context of adenosquamous lung carcinoma remains controversial.

In this study, we found that the EGFR mutation rate (29/106, 27.4%) was relatively high in adenosquamous lung carcinoma patients but had no effect on disease-free survival or overall survival. Furthermore, we demonstrated that elevated NSE and TMI were independently unfavorable predictors. No significant difference in disease-free survival or overall survival were observed between patients with high carcinoembryonic antigen (CEA), cytokeratin 19 fragments (Cyfra21-1) or squamous cell carcinoma antigen (SCCA) levels compared to those with lower levels.

Several studies have demonstrated that the survival rate of adenosquamous lung carcinoma patients is shorter than other types of non-small cell lung cancer. The reported 5-year survival rate for adenosquamous lung carcinoma patients has varied between 6.2% and 25.4% \[[@R1], [@R15]-[@R18]\]. In the present study, we observed that the 5-year survival rate to be approximately 25.3%. In addition, the high frequency of lymph nodal metastases (59/106, 55.7%) and advanced pathological stage (46/106, 43.4%) at surgery underscores the aggressive behavior of adenosquamous lung carcinoma. Moreover, more than half adenosquamous lung carcinoma patients who underwent complete surgical resection experienced distant metastases or local recurrences (68/106, 64.2%) including distant brain metastases (11/68), consistent with the results of a prior study \[[@R1]\].

A previous study found that the amount of adenocarcinoma components did not affect the survival rate, while another reported that adenocarcinoma predominant tumors were considered to be a worse prognostic factor \[[@R18]-[@R20]\]. Conversely, Gawrychowski et al observed that a balance of squamous and adenocarcinoma components had better prognosis than either being predominant \[[@R17]\]. In the present study we found no significant difference in disease-free survival or overall survival between adenosquamous lung carcinoma patients based on dominant component. This difference in results between our study and others could be attributed to different sample sizes, or the fact that biopsies come from small regions of the tumor which may underrepresent adenosquamous carcinoma histologic characteristics.

EGFR mutation has been reported to be a good outcome predictor for patients with non-small cell lung cancer. Consistent with previous studies \[[@R21], [@R22]\], we observed that EGFR mutation frequency was increased in never-smokers and in females. However, no correlation between EGFR mutation status and patient survival was observed, which may result from the low incidence of EGFR-TKI treatment in this cohort (5/29). Two additional reports were unable to detect a significant association between EGFR mutation and prognosis in patients who did not receive EGFR-TKI therapy \[[@R23], [@R24]\]. In addition, a prior study showed an adenosquamous lung carcinoma patient harboring EGFR-sensitizing mutation had a remarkable response to gefitinib \[[@R25]\]. Therefore EGFR tyrosine kinase inhibitors would be a reasonable therapeutic option to adenosquamous lung carcinoma patients due to the relatively high frequency of EGFR mutations in this cohort.

According to previous studies, serum NSE level in non-small cell lung cancer may reflect the heterogeneity and neuroendocrine phenotype and was as a prognostic factor for neuroendocrine lung tumors \[[@R26], [@R27]\]. However, the predictive value of NSE in non-small cell lung cancer are unclear, since several studies did not observe a prognostic role, while others have reported that elevated NSE is associated with poor prognosis \[[@R7], [@R8], [@R28]\]. NSCLC with neuroendocrine properties was previously reported to be chemosensitive but was associated with poorer outcomes similar to small cell lung cancer.\[[@R29]\] In another study, elevated serum NSE predicted NSCLC resistance to EGFR-TKIs and it was speculated that transition to small cell lung cancer occurred after acquisition of EGFR-TKI resistance \[[@R9]\]. Interestingly, sequential NSE level measurement has predicted tumor recurrence, dropping during effective treatment, but rising again after relapse \[[@R30], [@R31]\]. And Bastide et al. found adenosquamous lung carcinoma is more phenotypically similar to neuroendocrine tumors compared to adenocarcinoma lung cancer or squamous cell lung cancer \[[@R32]\]. Further, we confirmed that high NSE level in adenosquamous lung carcinoma confers a poorer prognosis. A strong positive association was identified between preoperative NSE and clinical stage as well as lymph node metastasis. Elevated NSE levels gave a poorer prognosis to patients with advanced staged tumors compared to those with earlier stage disease. These results suggest that NSE reflects tumor burden and aggressiveness, consistent with previous studies. Therefore, our results suggest that these patients should undertake a more aggressive clinical course.

Cyfra21-1 and CEA have been confirmed as valuable prognostic factors for NSCLC. Previous studies found that Cyfra21-1 tends to be more useful for squamous cell carcinoma diagnosis while CEA is predictive for adenocarcinoma.\[[@R10], [@R12], [@R33]\] In our study, elevated levels of neither Cyfra21-1 nor CEA were associated adenosquamous lung carcinoma patient prognosis. Interestingly, the TMI evaluating both Cyfra21-1 and CEA simultaneously was an independent prognostic marker for overall survival (HR = 2.479, 95% CI: 1.050-5.855, *P* = 0.038). This result might reflect that adenosquamous lung carcinoma stems from a monoclonal expansion of a single mutant progenitor cell clone, maintaining both adenocarcinoma and squamous cell carcinoma characteristics \[[@R32], [@R34], [@R35]\]. However, the molecular mechanism of trans-differentiation into adenocarcinoma or squamous cell carcinoma requires furthermore exploration.

Our retrospective study has some limitations. First, some data was censored, the patient sample size was relatively small, and patients undertook different chemotherapeutic regimens. In addition, we did not investigate the adenosquamous lung carcinoma components separately so it is not known which harbored identified EGFR mutations. It has been reported that adenocarcinoma and squamous cell carcinoma components can possess the same EGFR mutation, suggesting that the histologic origin of adenosquamous lung carcinoma can be monoclonal \[[@R22]\].

In conclusion, our results demonstrate that elevated preoperative NSE level has adverse predictive and prognostic value. In addition, TMI based on serum CEA and Cyfra21-1 is also an independent prognostic for overall survival. A larger prospective study will be needed to confirm these results.

PATIENTS AND METHODS {#s4}
====================

Patients {#s4_1}
--------

A total of 106 adenosquamous lung carcinoma patients who underwent curative-intent complete resection between January 2008 and January 2013 at the Tianjin Medical University Cancer Institute & Hospital were enrolled in this retrospective study. The study was approved by the Institutional Review Board of Tianjin Medical University Cancer Institute & Hospital and informed consent was obtained from all patients. The following patients are excluded: (1) locally advanced (stage IIIB), metastasized (stage IV), or postsurgically relapsed adenosquamous lung carcinoma; (2) insufficient tissue specimens or unavailable for genetic analysis; (3) blood samples not obtained before operation, or serum tumor marker records were unavailable; (4) patients who died within one month after surgery; (5) preoperative chemotherapy or radiotherapy; and (6) history of second primary cancer diagnosed within 5 years. Patient characteristics are shown in Table [1](#T1){ref-type="table"}.

In terms of World Health Organization histological classification (3rd edition), if the percentage of one of the tumor components was less than 10%, such cancer was defined according to predominating texture and added 'with elements' \[[@R3]\]. Such patients were not taken into account in this study. If each of the components account for 40-60%, such cases were regarded as balanced and classified according to adenocarcinoma and squamous cell carcinoma characteristics shown in each case into the following subgroups: Adenocarcinoma predominant group, in which the adenocarcinoma component was equal to or more than 60% of tumor cells; Squamous cell carcinoma predominant group, in which the adenocarcinoma component was less than 50%; and equal adenocarcinoma and squamous cell carcinoma group, in which the adenocarcinoma component was 50%-60%.

Measurement of serum NSE, CEA, Cyfra21-1 and SCCA levels and EGFR mutations {#s4_2}
---------------------------------------------------------------------------

Serum concentrations of NSE, CEA, Cyfra21-1 and SCCA were measured within 2 weeks before surgery by electrochemiluminescence immunoassay on Roche Analytics E170 Immunology Analyzer (Roche Diagnostics, China). Based on the manufacturer\'s recommendation, the following cut-offs for serum marker levels were used: NSE 15.2 ng/ml, CEA 5.0 ng/ml, Cyfra21-1 3.3 ng/ml and SCCA 1.5 ng/ml.

Tumor marker index (TMI) was defined by the geometric mean of normalized CEA and Cyfra21-1. It was calculated as described recently (TMI = square root of CEA concentration/5.0 ng/ml × Cyfra21-1 concentration/3.3 ng/ml). The cut-off point for TMI was 0.54 according to results of Muley et al \[[@R36]\].

EGFR mutations were identified by polymerase chain reaction based direct sequencing to detect the nucleotide sequencing of the kinase domain of EGFR of individual exons (18-21 exons).

Statistical analysis {#s4_3}
--------------------

Data are presented as the mean ± SD or median and IQR (intraquartile range). Fisher\'s exact test or chi-square test was conducted to compare the distribution of categorical variables. The Mann-Whitney U-test or Kruskal-Wallis one-way ANOVA test was used to compare continuous data. Overall survival (OS) was defined as the time from the date of surgery to the date of final follow-up or death from any cause. Disease-free survival (DFS) was calculated from the date of surgery until the date of the first recurrence or death from any cause. The survival curves were estimated using the Kaplan-Meier method, and differences were evaluated using the log-rank test. Hazard ratios (HR) and 95% confidence intervals (95% CI) were assessed by univariate and multivariate analyses using the Cox proportional hazards model. The independent prognostic factor was estimated by the Cox proportional hazards model using stepwise regression (backward selection). A *P* value less than 0.05 was considered to indicate a statistically significant difference. SPSS 22.0 for Windows (SPSS, Chicago IL) was performed to analyze data.

SUPPLEMENTARY MATERIALS TABLE {#s5}
=============================
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